Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysis

Therapeutic Innovation and Regulatory Science

Volumn 47, Issue 2, 2013, Pages 167-174

  Zhang, Jenny J ^a   Chen, Huanyu ^a   He, Kun ^a   Tang, Shenghui ^a   Justice, Robert ^a   Keegan, Patricia ^a   Pazdur, Richard ^a   Sridhara, Rajeshwari ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

bias; blinded independent central review (BICR); meta analysis; progression free survival (PFS)

Indexed keywords

ARTICLE; BLINDED INDEPENDENT CENTRAL REVIEW; BREAST METASTASIS; CANCER GROWTH; CANCER RISK; CARCINOID; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; META ANALYSIS; METASTATIC COLORECTAL CANCER; OVARY CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PUBLICATION; SOFT TISSUE SARCOMA;

EID: 84877630674     PISSN: 21684790     EISSN: 21649200     Source Type: Journal    
DOI: 10.1177/0092861512459733     Document Type: Article

References (12)

1. Amit O,Bushnell W,Dodd L,Roach N,Sargent D.Blinded independent central review of the progression-free survival endpoint.Oncologist. 2010;15:492-495.
2. Dodd LE,Korn EL,Freidlin B, et al.Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?.J Clin Oncol. 2008;26:3791-3796.
3. Dancey JE,Dodd LE,Ford R, et al.Recommendations for the assessment of progression in randomized cancer treatment trials.Eur J Cancer. 2009;45:281-289.
4. Stone AM,Bushnell W,Denne J, et al.Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.Eur J Cancer. 2011;47:1763-1771.
5. Amit O,Mannino F,Stone AM, et al.Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis.Eur J Cancer. 2011;47:1772-1778.
6. Pogue J,Walter SD,Yusuf S.Evaluating the benefit of event adjudication of cardiovascular outcomes in large sample RCTs.Clin Trials. 2009;6:239-251.
7. Pignatti F,Hemmings R,Jonsson B.Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?.Eur J Cancer. 2011;47:1759-1762.
8. Dodd LE,Korn EL,Freidlin B,Gray R,Bhattacharya S.An audit strategy for progression-free survival.Biometrics. 2011;67:1092-1099.
9. Korn EL,Dodd LE,Freidlin B.Measurement error in the timing of events: effect on survival analyses in randomized clinical trials.Clin Trials. 2010;7:626-633.
10. Fleischer F,Gaschler-Markefski B,Bluhmki E.How is retrospective independent review influenced by investigator-introduced information censoring: a quantitative approach.Stat Med. 2011;30:3373-3386.
11. Oncologic Drug Advisory Committee. April 12, 2011 Meeting. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/O ncologicDrugsAdvisoryCommittee/ucm235829.htm. Accessed April 18, 2012.
12. Tang PA,Pond GR,Chen EX.Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials.Ann Oncol. 2010;21:19-26.